Treatment with tolebrutinib delayed the time to onset of 6-month CDP by 31% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results